Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS: We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either ATRA plus arsenic trioxide for induction and consolidation therapy or standard ATRA-idarubicin induction therapy followed by three cycles of consolidation therapy with ATRA plus chemotherapy and maintenance therapy with low-dose chemotherapy and ATRA. The study was designed as a noninferiority trial to show that the difference between the rates of event-free survival at 2 years in the two groups was not greater than 5%. RESULTS: Complete remission was achieved in all 77 patients in the ATRA-arsenic trioxide group who could be evaluated (100%) and in 75 of 79 patients in the ATRA-chemotherapy group (95%) (P=0.12). The median follow-up was 34.4 months. Two-year event-free survival rates were 97% in the ATRA-arsenic trioxide group and 86% in the ATRA-chemotherapy group (95% confidence interval for the difference, 2 to 22 percentage points; P<0.001 for noninferiority and P=0.02 for superiority of ATRA-arsenic trioxide). Overall survival was also better with ATRA-arsenic trioxide (P=0.02). As compared with ATRA-chemotherapy, ATRA-arsenic trioxide was associated with less hematologic toxicity and fewer infections but with more hepatic toxicity. CONCLUSIONS: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL. (Funded by Associazione Italiana contro le Leucemie and others; ClinicalTrials.gov number, NCT00482833.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Self-citationShen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
van Dongen, J., Macintyre, E., Gabert, J., Delabesse, E., Rossi, V, Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401592 · Cited by 1,169
Self-citationSanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationUnited States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826 · cited 1×
“A genetic diagnosis could be established by detection of the PML-RARA fusion gene by means of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay,28,29 demonstration of the t(15;17) translocation by means of conventional karyotyping or fluorescence in situ hybridization (FISH),30 or evidence of a microspeck…”
Research works printed but not linked: 3
- Zhang P, 1996, Chin J Hematol, 17, 58
- Sanz MA, 2000, Blood, 96, 1247
- Grimwade D, 2000, Blood, 96, 1297
Cited by
Items 501–600 of 1,000
Acute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers
Forghieri, F., Nasillo, V., Bettelli, F., Pioli, V., Giusti, D., Gilioli, A., Mussini, C., Tagliafico, E., Trenti, T., Cossarizza, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031081 · Cited by 20
Self-citationRewriting the rules for care of MDS and AML patients in the time of COVID-19
Raza, A., Assal, A., Ali, A. M., & Jurcic, J. G. (2020) · Leukemia Research Reports · doi:10.1016/j.lrr.2020.100201 · Cited by 22
“[8] High-risk patients must still receive a regimen that includes a cytotoxic agent such as an anthracycline or gemtuzumab ozogamcin.”
Mutational profile of ZBTB16‐RARA‐positive acute myeloid leukemia
Fabiani, E., Cicconi, L., Nardozza, A. M., Cristiano, A., Rossi, M., Ottone, T., Falconi, G., Divona, M., Testi, A. M., Annibali, O., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3904 · Cited by 21
Self-citationGreve, G., Schiffmann, I., & Lübbert, M. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1987-1 · Cited by 20
Self-citationHe, Q., Sun, X., Zhang, M., Chu, L., Zhao, Y., Wu, Y., Zhang, J., Han, X., Guan, S., & Ding, C. (2022) · International Journal of Immunopathology and Pharmacology · doi:10.1177/20587384211073397 · Cited by 20
Hematology Emergencies in Adults With Critical Illness
Spring, J. L., & Munshi, L. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.02.004 · Cited by 25
Acute Promyelocytic Leukemia in Children and Adolescents
Stein, E. M., & Tallman, M. S. (2014) · Acta Haematologica · doi:10.1159/000365117 · Cited by 20
Treatment of paediatric APL: How does the therapeutic approach differ from adults?
Kutny, M. A., Gregory, J., & Feusner, J. H. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.04.007 · Cited by 20
“03), respectively [36,54].”
BackgroundMethodTorkildsen, S., Gorunova, L., Beiske, K., Tjønnfjord, G. E., Heim, S., & Panagopoulos, I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132736 · Cited by 20
“RNA-sequencing of a case of acute myeloid leukemia with the bone marrow karyotype 46, XY,t(2;14)(q22;q32)[5]/47,XY,idem,+?4,del(6)(q13q21)[cp6]/46,XY[4] showed that the t (2;14) generated a ZEB2-BCL11B chimera in which exon 2 of ZEB2 (nucleotide 595 in the sequence with accession number NM_014795.”
BackgroundTargeting Agents Alone to Cure Acute Promyelocytic Leukemia
Chen, S., & Chen, Z. (2013) · New England Journal of Medicine · doi:10.1056/nejme1304762 · Cited by 20
Yanada, M., Takami, A., Mizuno, S., Mori, J., Chou, T., Usuki, K., Uchiyama, H., Amano, I., Fujii, S., Miyamoto, T., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02759-y · Cited by 19
JAMY, O. H., Dhir, A., Costa, L. J., & Xavier, A. C. (2021) · Cancer · doi:10.1002/cncr.33914 · Cited by 19
A Superphane-based carcerand for arsenic detoxification via imprisoning arsenate
Zhou, W., Wang, F., Li, A., Bai, S., Feng, X., & He, Q. G. (2023) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2023.101295 · Cited by 19
Cytogenetics and genomics of acute myeloid leukemia
Snaith, O., Poveda-Rogers, C., Laczko, D. I., Yang, G., & Morrissette, J. J. D. (2023) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2023.101533 · Cited by 27
Recent advances in acute promyelocytic leukaemia
Ng, C. H., & Chng, W. J. (2017) · F1000Research · doi:10.12688/f1000research.10736.1 · Cited by 19
Zhang, X., Zhang, H., Chen, L.-M., Wang, M., Xi, J., Liu, X., Xie, M., Li, D., Gulati, E. S., Gong, S., et al. (2018) · Trials · doi:10.1186/s13063-018-2812-3 · Cited by 20
Bashash, D., Delshad, M., Riyahi, N., Safaroghli‐Azar, A., Pourbagheri‐Sigaroodi, A., & Momeny, M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.007 · Cited by 19
Wu, J., You, Y., Ma, Y., Kang, Y., Wu, T., Wu, X.-J., Hu, X., Meng, Q., Huang, Y., Zhang, N., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02759-5 · Cited by 19
Venetoclax for arsenic‐resistant acute promyelocytic leukaemia
Wang, Q. Q., Wang, H., Zhao, J., Naranmandura, H., Jin, J., & Zhu, H. (2022) · British Journal of Haematology · doi:10.1111/bjh.18061 · Cited by 24
Retinoic acid plus arsenic trioxide, the ultimate panacea for acute promyelocytic leukemia?
Lallemand-Breitenbach, V., & de Thé, H. (2013) · Blood · doi:10.1182/blood-2013-06-505115 · Cited by 22
Hong, J., Sui, P., Li, Y., Xu, K., Lee, J.-H., Wang, J., Shi, C., Zhang, P., Wingate, N., Noor, A., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.01.010 · Cited by 22
Zhang, H., Su, X., Guo, L., Zhong, L., Li, W., Yue, Z., Wang, X., Mu, Y., Li, X., Li, R., et al. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.10038 · Cited by 18
“Arsenic trioxide (ATO) has been successfully used to treat leukemia [5-8] and some solid malignant tumors [9, 10].”
BackgroundWeinhäuser, I., Pereira‐Martins, D. A., Rojas, C. A. O., Silveira, D. R., Simões, L. A. A., Bianco, T. M., Araujo, C. L., Koury, L. C. A., Melo, R. A. M., Bittencourt, R., et al. (2020) · Cancers · doi:10.3390/cancers12113134 · Cited by 18
“The cell cycle analysis in APL cells upon drug-treatment suggested that shSLIT2 cells are more resistant to ATO treatment as a result of increased cell proliferation at the early time points of the treatment.”
BackgroundSelf-citationMetabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia
Balasundaram, N., Ganesan, S., Chendamarai, E., Palani, H. K., Venkatraman, A., Alex, A. A., David, S., Kumar, S. P., Radhakrishnan, N. R., Yasar, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005300 · Cited by 21
PIN1 and CDK1 cooperatively govern pVHL stability and suppressive functions
Chen, J., Li, M., Liu, Y., Guan, T., Yang, X., Wen, Y., Zhu, Y., Xiao, Z., Shen, X., Zhang, H., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01128-x · Cited by 20
“All-trans retinoic acid (ATRA), approved by FDA for the treatment of Acute Promyelocytic Leukemia (APL) [27], has been reported to be a potent PIN1 inhibitor [28, 29].”
BackgroundChêne, C., Rongvaux-Gaïda, D., Thomas, M., Rieger, F., Nicco, C., & Batteux, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1149869 · Cited by 19
“ATO has been shown to be the most effective single agent for the treatment of APL and, following co-treatment with ATO and all-trans retinoic acid, long-term survival of patients with APL has increase to 80– 90% (20).”
BackgroundBraun, T., Cereja, S., Chevret, S., Raffoux, E., Beaumont, M., Detourmignies, L., Pigneux, A., Thomas, X., Bordessoule, D., Guerci‐Bresler, A., et al. (2015) · Cancer · doi:10.1002/cncr.29389 · Cited by 18
Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction
Li, J., Zhu, H., Hu, J., Mi, J., Chen, S., Chen, Z., & Wang, Z. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1603-1 · Cited by 22
“The success of ATO in chemotherapy-free induction and/or consolidation therapies [43, 44] provided a bright future for targeted therapy, without exposure to any conventional DNA-damaging chemotherapies in dealing with human malignancies.”
BackgroundResultStein, E. M., & Yen, K. E. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-122051 · Cited by 18
“Subsequently, ATRA + ATO (without chemotherapy) was shown to be at least not inferior, and possibly superior, to ATRA + chemotherapy in nonhigh-risk APL (Lo-Coco et al. 2013) and a feasible alternative to ATRA + idarubicin in low-risk patients (Burnett et al. 2015).”
BackgroundInfluentialArsenic trioxide and all‐trans retinoic acid treatment for childhood acute promyelocytic leukaemia
Strocchio, L., Gurnari, C., Santoro, N., Putti, M. C., Micalizzi, C., Zecca, M., Cuccurullo, R., Girardi, K., Diverio, D., Testi, A. M., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15507 · Cited by 18
Self-citationLi, Y., Thomas, D., Deutzmann, A., Majeti, R., Felsher, D. W., & Dill, D. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-53290-3 · Cited by 20
Rashid, A., Duan, X., Gao, F., Yang, M., & Yen, A. (2020) · Oncotarget · doi:10.18632/oncotarget.27508 · Cited by 18
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future
Gottardi, M., Sperotto, A. A., di Rorà, A. G. L., Padella, A., Cangini, D., Giannini, M. B., Simonetti, G., Martinelli, G., & Cerchione, C. (2020) · Minerva Medica · doi:10.23736/s0026-4806.20.07019-6 · Cited by 18
Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia
Wang, J., Tomlinson, B. K., & Lazarus, H. M. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01090-3 · Cited by 18
“non-specific cytotoxic chemotherapy [4].”
Murthy, H. S., & Wood, W. A. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0261-6 · Cited by 19
The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies
Rice, K. L., & de Thé, H. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12208 · Cited by 23
Gaillard, C., Tokuyasu, T. A., Rosen, G. P., Sotzen, J. R., Vitaliano-Prunier, A., Roy, R., Passegue, E. A., de Thé, H., Figueroa, M. E., & Kogan, S. C. (2015) · Haematologica · doi:10.3324/haematol.2014.123018 · Cited by 21
“respond to combination therapy with retinoic acid and arsenic trioxide.(1,2) Although treatable, the way in which”
BackgroundKuhn, M., Nabergoj, M., Sammartin, K., & Vianello, F. (2016) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2016.023 · Cited by 18
“Mediterr J Hematol Infect Dis 2016, 8(1): e2016023, DOI: http://dx.”
BackgroundLi, X., Li, Y., Zhang, L., Liu, X., Feng, L., & Wang, X. (2017) · Oncology Reports · doi:10.3892/or.2017.5945 · Cited by 18
Early mortality in acute promyelocytic leukemia: Potential predictors (Review)
Chen, C., Huang, X., Wang, K., Chen, K., Gao, D., & Qian, S. (2018) · Oncology Letters · doi:10.3892/ol.2018.7854 · Cited by 25
“This may be due to the reduced sensitivity to ATRA/ATO and the delay in administering ATO, which has been demonstrated by an Italian/German/Austrian cooperative group study that suggested earlier administration of ATO may overcome the negative effect of complex karyotypes (77).”
Zhang, Y., Li, G., Liu, X., Song, Y., Xie, J., Li, G., Ren, J., Wang, H., Mou, J., Dai, J., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8010 · Cited by 18
“Chemotherapy with all-trans retinoic acid, anthracycline antibiotics and arsenic trioxide is a typical treatment for leukemia, and has been widely used with satisfactory effect (3).”
BackgroundSun, J., Zhu, J., Zhou, D., Zhu, L., Yang, X., Xie, M., Li, L., Huang, X., Zhu, M., Zheng, Y., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.08.001 · Cited by 18
Ye, Y., Ricard, L., Siblany, L., Stocker, N., de Vassoigne, F., Brissot, É., Lamarthée, B., MEKINIAN, A., Mohty, M., Gaugler, B., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.016 · Cited by 19
Takeshita, A., Asou, N., Atsuta, Y., Furumaki, H., Sakura, T., Ueda, Y., Sawa, M., Dobashi, N., Taniguchi, Y., Suzuki, R., et al. (2020) · Cancers · doi:10.3390/cancers12061444 · Cited by 17
Ngo, S. D., Oxley, E. P., Ghisi, M., Garwood, M. M., McKenzie, M. D., Mitchell, H. L., Kanellakis, P., Susanto, O., Hickey, M. J., Perkins, A. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26849-w · Cited by 17
Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective
Bleve, A., Consonni, F. M., Porta, C., Garlatti, V., & Sica, A. (2022) · Cancers · doi:10.3390/cancers14030510 · Cited by 21
Castro-Guijarro, A. C., Mondaca, J. M., Fernandez-Muñoz, J. M., Vanderhoeven, F., Uzair, I., Redondo, A. L., Zoppino, F. C. M., Sanchez, A. M., & Flamini, M. I. (2022) · Cells · doi:10.3390/cells11192988 · Cited by 19
Wang, J., Liu, Y., Hu, J., & Chen, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114464 · Cited by 18
A novel mesenchymal stem cell-based regimen for acute myeloid leukemia differentiation therapy
Sun, L., Yang, N., Chen, B., Bei, Y., Kang, Z., Zhang, C., Zhang, N., Xu, P., Yang, W., Wei, J., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.007 · Cited by 19
Mu, X., Chen, C., Dong, L., Kang, Z., Sun, Z., Chen, X., Zheng, J., & Zhang, Y. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023101 · Cited by 19
“Recently, several types of leukaemia have been profoundly attenuated with targeted drugs; for example, 80%‒90% of acute promyelocytic leukaemia (APL) patients were cured after the application of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) [6], almost all BCR-ABL1+ CML patients benefited from tyrosine kin…”
BackgroundBacker, M. D., Sengar, M., Mathews, V., Salvaggio, S., Deltuvaite‐Thomas, V., Chiêm, J., Saad, E. D., & Buyse, M. E. (2023) · Clinical Trials · doi:10.1177/17407745231206465 · Cited by 19
“11,12 16 Of note, and despite a generally improved tolerability from targeted therapy, toxicity remains a problem, particularly the ‘‘dif-ferentiation syndrome’’ associated with the use of ATRA.”
BackgroundAbdel‐Wahab, B. A., El‐Shoura, E. A. M., Habeeb, M. S., & Zaafar, D. K. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111325 · Cited by 17
CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias
Vedula, R. S., Karp, H. Q., Koob, J. G., Lim, F., Garcia, J. S., Winer, E. S., Luskin, M. R., Ghiaur, G., Kim, A. S., Beppu, L. W., et al. (2024) · Blood · doi:10.1182/blood.2023022908 · Cited by 17
Cicconi, L., Bisegna, M. L., Gurnari, C., Fanciullo, D., Piciocchi, A., Marsili, G., Minotti, C., Scalzulli, E., Mandelli, B., Guarnera, L., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19759 · Cited by 18
Self-citationFilippi, A., Deculescu-Ioniță, T., Hudiță, A., Baldasici, O., Gălățeanu, B., & Mocanu, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020631 · Cited by 18
“The administration of retinoic acid in combination with chemotherapy or arsenic trioxide induced PML remission in 95 and 100% of patients, respectively [317].”
Liu, Y., He, P., Cheng, X., & Zhang, M. (2015) · Oncology Letters · doi:10.3892/ol.2015.3308 · Cited by 17
“Reti-noic acid (RA)-based chemotherapy is the standard treatment regimen administered for APL (4,5).”
Dembitz, V., Lalić, H., Ostojić, A., Vrḫovac, R., Banfíƈ, H., & Višnjić, D. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1776-2 · Cited by 19
“The latest results of clinical studies instituting ATO in first-line treatment showed that ATRA plus arsenic trioxide might be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL, suggesting the possibility of leukemia treatment without any DNA-damaging chemotherapy [2].”
BackgroundAbla, O., Kutny, M. A., Testi, A. M., Feusner, J. H., Creutzig, U., Gregory, J., Gibson, B. E. S., Leverger, G., Ribeiro, R. C., Smith, O. P., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14313 · Cited by 17
“In clinical trials utilizing ATO induction, predominantly of adults, the rate of refractory APL is virtually zero (Ravandi et al, 2009; Mathews et al, 2010; Zhou et al, 2010; Iland et al, 2012; Lo-Coco et al, 2013, 2016).”
BackgroundPaige, E. K., Haywood, P., Xie, M., Worth, L. J., Thursky, K., Urbancic, K. F., Bajel, A. R., & Slavin, M. A. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1590570 · Cited by 17
“chemotherapy, is significantly lower [38,39].”
Zhang, H., Jin, B., Liu, L., Li, H., Zheng, X., Li, M., He, R., & Wang, K. (2023) · Biological Trace Element Research · doi:10.1007/s12011-023-03577-4 · Cited by 17
Sive, J. I., Basilico, S., Hannah, R., Kinston, S. J., Calero-Nieto, F. J., & Göttgens, B. (2016) · Leukemia · doi:10.1038/leu.2015.172 · Cited by 17
Biology and management of therapy-related acute promyelocytic leukemia
Lo‐Coco, F., Hasan, S. K., Montesinos, P., & Sanz, M. Á. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000013 · Cited by 17
Self-citationDass, J., Dayama, A., Seth, T., Mahapatra, M., Mishra, P., & Saxena, R. (2015) · Indian Journal of Cancer · doi:10.4103/0019-509x.176731 · Cited by 17
Acute Promyelocytic Leukemia: A Perspective
Ravandi, F., & Stone, R. M. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.06.037 · Cited by 17
Bryant, A. L., Drier, S., Lee, S., & Bennett, A. V. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.06.006 · Cited by 17
The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning From Mouse Models
Fisher, J. N., Kalleda, N., Stavropoulou, V., & Schwaller, J. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000152 · Cited by 23
Nuclear Receptors as Potential Therapeutic Targets for Myeloid Leukemia
Pan, P., & Chen, X. (2020) · Cells · doi:10.3390/cells9091921 · Cited by 18
“ATRA + ATO 156 APL patients Induced complete remission and improved 2-year event-free survival rates and overall survival [47]”
BackgroundGrimwade, D. J., & Freeman, S. D. (2014) · Hematology · doi:10.1182/asheducation.v2014.1.222.3884425 · Cited by 41
Creutzig, U., Kutny, M. A., & Schlenk, R. F. (2016) · Pediatric oncology · doi:10.1007/978-3-319-33679-4_6 · Cited by 17
Self-citationCingam, S. R., & Koshy, N. V. (2021) · StatPearls · Cited by 16
Efficace, F., Platzbecker, U., Breccia, M., Cottone, F., Carluccio, P., Salutari, P., Bona, E. D., Borlenghi, E., Autore, F., Levato, L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004649 · Cited by 18
Self-citationHow to avoid early mortality in acute promyelocytic leukemia
Odetola, O. E., & Tallman, M. S. (2023) · Hematology · doi:10.1182/hematology.2023000477 · Cited by 18
Long, Z., Hu, Y., Li, X.-D., He, Y. J., Xiao, R.-Z., Fang, Z.-G., Dong-ning, W., Liu, J., Yan, J., Huang, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104610 · Cited by 16
Iland, H. J., Wei, A. H., & Seymour, J. F. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.04.003 · Cited by 16
“The maintenance question has primarily been studied in the context of ATRA þ chemotherapy protocols, whereas the APL0406 study [78] showed superiority for ATRA þ ATO without maintenance over ATRA þ chemotherapy with maintenance in non-high-risk patients.”
MethodGenomic amplification of MYC as double minutes in a patient with APL-like leukemia
Poddighe, P. J., Wessels, H. M. C., Merle, P. A., Westers, M., Bhola, S. L., Loonen, A. H., Zweegman, S., Ossenkoppele, G. J., & Wondergem, M. J. (2014) · Molecular Cytogenetics · doi:10.1186/s13039-014-0067-6 · Cited by 16
Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells
Misra, S., Selvam, A. K., Wallenberg, M., Ambati, A., Matolcsy, A., Magalhaes, I., Lauter, G., & Björnstedt, M. (2016) · Oncotarget · doi:10.18632/oncotarget.12531 · Cited by 16
“To this end, the combined use of ATRA and ATO/chemotherapy presents a remarkable success in molecular targeted therapy [9, 29-31].”
BackgroundCan Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice?
Luskin, M. R., & Stone, R. M. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.021675 · Cited by 17
Novel Drug Therapies in Myeloid Leukemia: a Patent Review
Horne, G. A., Kinstrie, R., & Copland, M. (2015) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.15.3 · Cited by 18
Labrador, J., Luño, E., Vellenga, E., Brunet, S., Gonzalez-Campos, J. A., Chillón, C., Hołowiecka, A., Esteve, J., Bergua, J., González-Sanmiguel, J. D., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1522438 · Cited by 16
“[17,18], making less relevant the impact of prognostic”
BackgroundEfficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1
Paubelle, É., Pleșa, A., Hayette, S., Elhamri, M., Zylbersztejn, F., Hermine, O., Salles, G. A., & Thomas, X. (2019) · Oncology and Therapy · doi:10.1007/s40487-019-0095-9 · Cited by 16
Brandwein, J. M., Zhu, N. Y., Kumar, R., Leber, B. F., Sabloff, M., Sandhu, I., Kassis, J., Olney, H. J., Elemary, M., & Schuh, A. C. (2017) · Europe PMC (PubMed Central) · Cited by 23
Klepin, H. D., Neuendorff, N. R., Larson, R. A., Hamaker, M. E., Breccia, M., Montesinos, P., & Córdoba, R. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.03.019 · Cited by 17
Self-citationNguyen, C. H., Grandits, A. M., Purton, L. E., Sill, H., & Wieser, R. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1810402 · Cited by 19
“[7] Lo-Coco F, Avvisati G, Vignetti M, et al.”
BackgroundIvanov, V., Yeh, S., Mayer, J., Saini, L., Ünal, A., Boyiadzis, M. M., Hoffman, D., Kang, K., Addo, S. N., Mendes, W., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0450 · Cited by 18
Molecular Mechanisms of the Antileukemia Activities of Retinoid and Arsenic
Nitto, T., & Sawaki, K. (2014) · Journal of Pharmacological Sciences · doi:10.1254/jphs.14r15cp · Cited by 16
Holloway, R. W., Thomas, M. L., Cohen, A., Bharadwaj, A. G., Rahman, M., Marcato, P., Marignani, P. A., & Waisman, D. M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0954-6 · Cited by 16
Breccia, M., & Foà, R. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2019.1562332 · Cited by 16
“Also, the 2-year OS probability was significantly higher for the ATO arm (99% vs 91%), while the 2-year cumulative incidence of relapse (CIR) was not significantly different between the two treatment arms (1% vs 6%) [44].”
BackgroundSelf-citationLou, Y., Suo, S., Tong, Y., Tong, H., Qian, W., Meng, H., Mai, W., Huang, J., Yu, W., & Jin, J. (2014) · Annals of Hematology · doi:10.1007/s00277-013-2000-1 · Cited by 15
Cheli, E., Chevalier, S., Kosmider, O., Eveillard, M., Chapuis, N., Pleșa, A., Heiblig, M., Andre, L., Pouget, J., Mossuz, P., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280406 · Cited by 15
Viragova, S., Aparicio, L., Palmerini, P., Zhao, J., Salazar, L. E. V., Schurer, A., Dhuri, A., Sahoo, D., Moskaluk, C. A., Rabadán, R., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad062 · Cited by 15
Immunotherapy in Acute Myeloid Leukemia: A Literature Review of Emerging Strategies
Guarnera, L., Bravo‐Pérez, C., & Visconte, V. (2023) · Bioengineering · doi:10.3390/bioengineering10101228 · Cited by 17
Jen, W., Sasaki, K., Rausch, C. R., Dinardo, C. D., Kadia, T. M., Yilmaz, M. E., Borthakur, G. M., Alvarado, Y., McCue, D. L., McCue, D. A., et al. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2290467 · Cited by 15
“The differentiating agents all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) have transformed the treatment landscape of APL, with long-term overall survival rates exceeding 90% [2–6].”
BackgroundResultUltrathin 2D As2Se3 Nanosheets for Photothermal-Triggered Cancer Immunotherapy
Zhang, J., Qin, Y., Chen, Y., Zhao, X., Wang, J., Wang, Z., Li, J., Zhao, J., Liu, S., Guo, Z., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c10432 · Cited by 17
Golgi apparatus targeted therapy in cancer: Are we there yet?
Lee, Z. Y., Lee, W. H., Lim, J. S., Ali, A. A. A., Loo, J. S. E., Wibowo, A., Mohammat, M. F., & Foo, J. B. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122868 · Cited by 19
Recent Developments in Differentiation Therapy of Acute Myeloid Leukemia
Testa, U., Castelli, G., & Pelosi, E. (2025) · Cancers · doi:10.3390/cancers17071141 · Cited by 18
“…vulnerability of APL has been exploited and allowed for the development of a curative dual differentiation therapy based on the association of ATRA and arsenic trioxide (ATO), leading to more than 90% of patients being cured from this leukemia without the use of cytotoxic chemotherapy [7].”
Hecht, A., Nolte, F., Nowak, D., Nowak, V., Reinwald, M., Hanfstein, B., Faldum, A., Büchner, T., Spiekermann, K., Sauerland, C., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.990011 · Cited by 15
Almeida, L. Y., Pereira‐Martins, D. A., Weinhäuser, I., Rojas, C. A. O., Cândido, L. A., Lange, A. P., ABREU, N. F. D., Mendonza, S. E. S., Wagatsuma, V. M. D. D., do Nascimento, M. C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.686445 · Cited by 16
“The clinical introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) revolutionized the treatment of acute promyelocytic leukemia (APL), leading to a disease-free survival rate of 80-90% (1).”
BackgroundExploring the Potential of Metal‐Based Candidate Drugs as Modulators of the Cytoskeleton
Borutzki, Y., Skos, L., Gerner, C., & Meier, S. M. (2023) · ChemBioChem · doi:10.1002/cbic.202300178 · Cited by 17
Yue, Z., Zhong, L., Mou, Y., Wang, X., Zhang, H., Wang, Y., Xia, J., Li, R., & Wang, Z. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.12450 · Cited by 15
“Recently, ATO has been used to treat various malignancies and has been shown to have significant benefit in the treatment of acute promyelocytic leukemia [6-8] as well as a broad spectrum of hematologic and solid tumors in preclinical models [9, 10].”
BackgroundZhu, H., Hu, J., Li, X., Chen, L., Zhao, H., Zhou, W., Wang, L., Zhao, X., Zhang, Y., Chen, Y., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13375 · Cited by 15
Metadata
- Authors
- Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., Specchia, G., Sica, S., Divona, M., Levis, A., Fiedler, W., Cerqui, E., Breccia, M., Fioritoni, G., Salih, H. R., Cazzola, M., Melillo, L., Carella, A. M., Brandts, C. H., Morra, E., von Lilienfeld-Toal, M., Hertenstein, B., Wattad, M., Lübbert, M., Hänel, M., Schmitz, N., Link, H., Kropp, M. G., Rambaldi, A., La Nasa, G., Luppi, M., Ciceri, F., Finizio, O., Venditti, A., Fabbiano, F., Döhner, K., Sauer, M., Ganser, A., Amadori, S., Mandelli, F., Döhner, H., Ehninger, G., Schlenk, R. F., & Platzbecker, U.
- ORCID
- Avvisati, Giuseppe
- Vignetti, Marco
- Thiede, Christian
- Iacobelli, Simona
- Ferrara, Felicetto
- Fazi, Paola
- Cicconi, Laura
- Specchia, Giorgina
- Sica, Simona
- Fiedler, Walter
- Breccia, Massimo
- Salih, Helmut R.
- Cazzola, Mario
- Melillo, Lorella
- Carella, Angelo M.
- Brandts, Christian H.
- Hertenstein, Bernd
- Lübbert, Michael
- Hänel, Matthias
- Schmitz, Norbert
- Link, Hartmut
- Rambaldi, Alessandro
- Luppi, Mario
- Ciceri, Fabio
- Finizio, Olimpia
- Venditti, Adriano
- Döhner, Konstanze
- Ganser, Arnold
- Amadori, Sergio
- Döhner, Hartmut
- Ehninger, Gerhard
- Schlenk, Richard F.
- Platzbecker, Uwe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-11
- Volume
- 369
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2129338773
- Cited by
- 1,611
- References
- 42
- Citations by year
- 2026: 83 · 2025: 89 · 2024: 132 · 2023: 144 · 2022: 110 · 2021: 147 · 2020: 137 · 2019: 125 · 2018: 122 · 2017: 107 · 2016: 117 · 2015: 144 · 2014: 119 · 2013: 33
- FWCI
- 61.62
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- acute promyelocytic leukemia, all-trans retinoic acid, arsenic trioxide, idarubicin, induction therapy, consolidation therapy, maintenance therapy, event-free survival, overall survival, complete remission, hematologic toxicity, hepatotoxicity
- MeSH terms
- Arsenic Trioxide, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Arsenicals, Female, Humans, Male, Middle Aged, Neutropenia, Oxides, Thrombocytopenia, Tretinoin, Leukemia, Promyelocytic, Acute, Disease-Free Survival, Young Adult, Maintenance Chemotherapy, Induction Chemotherapy, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.